A phase II study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcomas

BACKGROUND: Relapsed and refractory sarcomas continue to have poor survival rates. The cancer stem cell (CSC) theory provides a tractable explanation for the observation that recurrences occur despite dramatic responses to upfront chemotherapy. Preclinical studies demonstrated that inhibition of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Trucco, Matteo M., Meyer, Christian F., Thornton, Katherine A., Shah, Preeti, Chen, Allen R., Wilky, Breelyn A., Carrera-Haro, Maria A., Boyer, Lillian C., Ferreira, Margaret F., Shafique, Umber, Powell, Jonathan D., Loeb, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217787/
https://www.ncbi.nlm.nih.gov/pubmed/30410720
http://dx.doi.org/10.1186/s13569-018-0107-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217787/
https://www.ncbi.nlm.nih.gov/pubmed/30410720
http://dx.doi.org/10.1186/s13569-018-0107-9

Ejemplares similares